FindTrial
Sign In

A phase 3 clinical trial of duloxetine in patients with osteoarthritis

A phase 3 clinical trial of duloxetine in patients with osteoarthritis

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222625
Enrollment
Unknown
Registered
2014-10-14
Start date
2014-10-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis

Interventions

investigational material(s) Generic name etc : LY248686 INN of investigational material : Duloxetine Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administra

Sponsors

Shionogi & Co., Ltd.
Lead Sponsor
Eli Lilly and Company
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Participants meet the ACR criteria for idiopathic osteoarthritis of the knee. And et al.

Exclusion criteria

Exclusion criteria: Participants with past history of multiple episodes of drug allergy. Participants previously treated with duloxetine. And et al.

Design outcomes

Primary

MeasureTime frame
Change from baseline in Brief Pain Inventory (BPI)-average pain score—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026